
SOPH Stock Forecast & Price Target
SOPH Analyst Ratings
Bulls say
Sophia Genetics is viewed favorably because its cloud-based, pay-per-analysis SaaS model turns rising genomic complexity into recurring revenue, with 2025 revenue of $77.3M growing 19% YoY and 1Q26 growth accelerating to 22% YoY while adjusted gross margin expanded to 75.4%. The company’s moat is reinforced by a sequencer-agnostic platform used by roughly 1,000 hospitals and laboratories across 75 countries, a database of more than 2.5 million genomic profiles, and strong retention metrics including below 1% annualized churn and 117% net dollar retention in 1Q26. Its outlook is further supported by marquee U.S. wins such as MSK, MD Anderson, and two large integrated health systems representing about 60K analyses annually, plus emerging biopharma momentum from AstraZeneca, Myriad Genetics, and Johnson & Johnson.
Bears say
Sophia Genetics is viewed negatively because its core DDM platform still appears dependent on broad commercial expansion, yet 2024 showed only 4% revenue growth despite 11% volume growth, implying a 6-7% decline in revenue per analysis and weaker pricing power. The business also remains unprofitable, with FY2025 net loss of $79.0M, while future profitability depends on execution against a complex, fragmented healthcare data market that is constrained by integration, reimbursement, and privacy issues. Although liquid biopsy grew more than 100% YoY in 1Q26, about half of those accounts were still not live, and ongoing Guardant Health litigation plus dilution and cybersecurity risks could further pressure margins and shareholder value.
This aggregate rating is based on analysts' research of Sophia Genetics SA and is not a guaranteed prediction by Public.com or investment advice.
SOPH Analyst Forecast & Price Prediction
Start investing in SOPH
Order type
Buy in
Order amount
Est. shares
0 shares